#Lonza's efforts to help ensure reliable supply at unprecedented speed in the development of a COVID-19 vaccine reveal how CDMOs innovation can both reduce risk and increase speed-to-market. @PharmTechGroup https://t.co/kDvLhcyrR9 #NextTogether
— Lonza Pharma & Biotech (@LonzaPB) September 8, 2020
With the expansion of our microbial manufacturing facilities in Visp, Switzerland, #Lonza's experts share how our expertise in end-to-end services ensures our partners' live-saving therapies are accessible to the patients who need them. https://t.co/B0VF6423wP #NextTogether
— Lonza Pharma & Biotech (@LonzaPB) September 4, 2020
In @AmPharmRev, #Lonza experts write about how using lipophilic salt forms when creating lipid-based formulations (LBFs) may help improve #bioavailability, reduce pill burden & limit adverse effects of low-soluble compounds. #NextTogether #BAEnhancement https://t.co/K2zOaTFaRi
— Lonza Pharma & Biotech (@LonzaPB) September 3, 2020
#Lonza's David Lyon shared with @AmPharmRev how our end-to-end services help solve customers' #bioavailability challenges in small molecule development, shortening time to clinic and to market. #NextTogether https://t.co/Mrst0cMtTB
— Lonza Pharma & Biotech (@LonzaPB) August 20, 2020
In @PharmasAlmanac's latest edition, #Lonza's David Lyon and Gavin Samuels identified the most impactful molecules in history, including penicillin, aspirin, saquinavir, infliximab and adalimumab. https://t.co/FSoFOV1WTC #NextTogether
— Lonza Pharma & Biotech (@LonzaPB) August 5, 2020
Innovations like molecular dynamics simulation (MDS) can help in selecting the right enabling technology for #BAenhancement. #Lonza experts share how MDS can accelerate development timelines for oral delivery of peptide products #NextTogether https://t.co/mdxE2aifoH
— Lonza Pharma & Biotech (@LonzaPB) July 28, 2020
Last week, #Lonza's David Lyon presented at the 2020 @FDDCongress about how in vitro tests can help select the right tech to enhance #bioavailability. If you missed it, visit our website to learn how Lonza can boost your molecule's bioavailability. https://t.co/QxiOIUxNf2 pic.twitter.com/17alwiI7zc
— Lonza Pharma & Biotech (@LonzaPB) July 15, 2020
Residual impurities need to be identified to maintain high quality and patient safety. #Lonza's Michael Jahn shares the importance of having a risk-based approach in identifying, assessing and removing residual impurities. #NextTogether #Biotechnology https://t.co/TibcQCY2Fn
— Lonza Pharma & Biotech (@LonzaPB) July 9, 2020
#Lonza has announced new investments in our global particle engineering network to expand capacity and introduce new specialized capabilities, boosting our #spraydrying and #micronization technologies for #bioavailability enhancement #NextTogether https://t.co/zsFEiBgiM7 pic.twitter.com/QnMnSNyUA4
— Lonza Pharma & Biotech (@LonzaPB) July 3, 2020
Spray drying is an effective #bioavailability enhancement method, but challenges may arise with complex compounds. In @manchemparma, #Lonza experts describe best practices for designing spray drying process to address issues and speed drug development. https://t.co/7oK2d7fw5j
— Lonza Pharma & Biotech (@LonzaPB) June 11, 2020
Announcing our Anthos Therapeutics partnership, a clinical-stage biotech developing a unique dual Factor XI/XIa antibody for thrombotic conditions, utilizing our global network of process development and GMP-manufacturing facilities. https://t.co/q2cRyw0xEz #NextTogether #Lonza pic.twitter.com/7IGTlgV5w2
— Lonza Pharma & Biotech (@LonzaPB) June 11, 2020
This F1000 article describes a 3D brain endothelium/astrocyte co-culture in compressed collagen that forms an effective blood-brain barrier model for nanoparticle research using our RAFT(TM) 3D Culture System. #drugdiscovery #lifesciences #cellbiologyhttps://t.co/uAVkGuMzdX pic.twitter.com/HTGRvU881g
— Lonza BioResearch Solutions (@LonzaBioRes) September 8, 2020
The properties and behavior of cancer cells and tumoroids are influenced by the surrounding extracellular matrix. Check out this article describing how to build and analyze a 3D tumoroid model embedded in ECM. https://t.co/DFd7u2CqNT#drugdiscovery #lifesciences @CisbioBioassays pic.twitter.com/1zOQQJYim0
— Lonza BioResearch Solutions (@LonzaBioRes) September 1, 2020
Check out our new web page about cancer immunotherapy. It provides a comprehensive introduction, discusses current strategies with focus on CAR-T cell therapies and offers many useful tools and technical resources for on-demand viewing or download. https://t.co/eXV919iBbn pic.twitter.com/6eHA6q0HBk
— Lonza BioResearch Solutions (@LonzaBioRes) August 20, 2020
Identifying potential treatments for COVID-19 is of utmost importance right now. This blog post highlights some recent work done for high throughput screening of drug candidates for SARS-CoV-2 using software designed for phenotypic analysis. https://t.co/97vni1cFFs #lifesciences pic.twitter.com/0JxXhIqQhz
— Lonza BioResearch Solutions (@LonzaBioRes) August 12, 2020
Need help with primary hepatocyte #transfection? Read this white paper detailing how we used Nucleofector(TM) technology to easily transfect primary hepatocytes: https://t.co/rpfWsAKIWg #lifesciences pic.twitter.com/vAp0bi72tJ
— Lonza BioResearch Solutions (@LonzaBioRes) August 11, 2020
In a recent Outsourcing-Pharma article, Lonza #drugdiscovery expert, Katrin Hoeck, explains how the proper biological models can enhance drug discovery and development. Read the full article here: https://t.co/5OPr4eh6d3 #lifesciences
— Lonza BioResearch Solutions (@LonzaBioRes) August 5, 2020
Looking for a protein production medium with high cell viability and low lactate levels, offering a consistent yield? Download our poster where we show comparison data on eCHO™ Basal Medium combined with eCHO™ Feed in a fed-batch culture. https://t.co/4t89dqKtew pic.twitter.com/LxHr2oXNE7
— Lonza BioResearch Solutions (@LonzaBioRes) July 28, 2020
In a recent interview with @ddwjournal, #DrugDiscovery expert, Katrin Hoeck, explains how advanced #3Dcellculture technologies can build #biologicallyrelevant models to assess toxicity and specificity of on- and off-target effects in early stages: https://t.co/7Ll2YcrxwT pic.twitter.com/3jb7H7GO8q
— Lonza BioResearch Solutions (@LonzaBioRes) July 23, 2020
Lonza has launched the GSv9™ Media and Feeds Platform, developed specifically for our GS Gene Expression System®, for the production of therapeutic recombinant proteins and antibodies. Find out more and contact us to discuss your needs. https://t.co/m3kPrUWvDZ pic.twitter.com/sxTJ8bds6e
— Lonza BioResearch Solutions (@LonzaBioRes) June 11, 2020
[PRESS RELEASE] Lonza is partnering with @CELLINK to offer a comprehensive #3Dbioprinting solution to advance #3Dcellculture workflows: https://t.co/uOQyFWyADE #drugdiscovery pic.twitter.com/HPK6KZ7uTX
— Lonza BioResearch Solutions (@LonzaBioRes) June 10, 2020
Take a look at a recent interview with @biocompare, where Lonza Media expert, Nicole Wellens, discusses her top tips for improving #cryopreservation techniques, such as using Lonza’s TheraPEAK™ ProFreeze™ Freezing Medium: https://t.co/DZXufI6atT pic.twitter.com/jK98mD7bld
— Lonza BioResearch Solutions (@LonzaBioRes) June 9, 2020
Albert Baehny, Chairman and CEO of @LonzaGroup: «We are quite optimistic that the #vaccine of Moderna will work»$LONN $MRNA #Covid19 @moderna_txhttps://t.co/mKYCAiRyyU
— TheMarket (@TheMarket_CH) August 27, 2020
Manufacturing challenges and enabling current and emerging applications in #iPSC-based therapies. Read more in this free commentary from the experts at @Lonzagroup. #RMNiPSCexpansion https://t.co/JDqvWSdOXb
— RegMedNet (@RegMedNet) July 16, 2020
#Lonza announced that the first patient has been treated at Sheba Medical Center with a CD19 CAR-T cell immunotherapy manufactured using Lonza’s Cocoon® Platform. This approach will make lifesaving therapies available to many more patients in need. https://t.co/1rzzC7nBHe pic.twitter.com/aH2YIofzj8
— Lonza (@LonzaGroup) September 8, 2020
#Lonza announced a collaboration with Isoplexis to provide Lonza’s Cocoon® Platform with high quality biological analytics. With Isoplexis' IsoLight® technology, Lonza's cell therapy manufacturing will be more precise and effective. https://t.co/T0qr6DzIJl pic.twitter.com/XOYYbG8Ivy
— Lonza (@LonzaGroup) August 20, 2020
Cannabinoids are a novel treatment option for a range of conditions, including autoimmune and other immune-related diseases. In the new #AViewOn episode, @DrHestericova speaks with Alain Rolland of Emerald Health Pharmaceuticals about #cannabinoid science https://t.co/jlt8CdjgWE
— Lonza (@LonzaGroup) August 20, 2020
Our NUGEN® NR Wipes have been nominated for this year’s World Of Wipes® Innovation Award #Wipes20 #WipesCon. The WOW Conf will be held from Aug 25-27th, all virtual, the winner to be announced on the final day#keepingourworldhealthy #disinfection #innovation #norinse #NRwipes pic.twitter.com/8N6O1x3wIv
— Lonza (@LonzaGroup) August 18, 2020
This week our Williamsport facility was proud to be recognized by @RepFredKeller, for all its work to control and contain the spread of #COVID19. We are resolved to continue to play our part in the fight against the coronavirus, as a supplier of essential products and services. https://t.co/5rqR60xfTX
— Lonza (@LonzaGroup) August 13, 2020
#Lonza announced an expansion of our microbial manufacturing facilities in Visp, CH housing Lonza’s Ibex™ Solutions. Focused on speed to market, the expansion will support customers, like @Servier, from clinical supply to commercial production. https://t.co/lijb0ubBz2
— Lonza (@LonzaGroup) August 4, 2020
#Lonza continues a long-term partnership with @KodiakSciences to commercially manufacture KSI-301, an ABC for retinal diseases. Lonza’s leadership in bioconjugation and complex supply chains will help Kodiak effectively scale up. pic.twitter.com/aK4X53sFBT
— Lonza (@LonzaGroup) July 28, 2020
Key message from Albert M. Baehny, Chairman and CEO ad interim, on our #LonzaHalfYear2020 results:https://t.co/7eO6VcbW5b pic.twitter.com/KAsHS8Y5zm
— Lonza (@LonzaGroup) July 24, 2020
Listen to the new episode of #AViewOn #podcast where Lonza's @DrHestericova speaks to Silviu Itescu, the CEO of @Mesoblast, about using mesenchymal #stemCells to treat severe cases of #Covid19.
Access the podcast episode here: https://t.co/wDeVSAzQv3 pic.twitter.com/XfRn81L7Wu
— Lonza (@LonzaGroup) July 20, 2020
What do we know about #PAH? There are many types including idiopathic (the most common), heritable, associative, and drug-induced. All are treated similarly, but the prognosis varies. Our goal – to resolve the disease itself. #WithYouUntilPHIsnt @JanssenGlobal pic.twitter.com/xdwhLNoqYe
— Actelion (@actelion_com) September 8, 2020
The international #PH patient and carer survey found that the impact of PH extends beyond the physical symptoms of the disease, affecting many parts of someone’s life. To read the full survey results visit https://t.co/gkSen5DqTd #WithYouUntilPHIsnt pic.twitter.com/e8KmOfQFT6
— Actelion (@actelion_com) August 31, 2020
It’s important to try to stay positive whilst living with pulmonary hypertension (#PH). Catarina would advise others to, ‘Never give up, because I never gave up and now I feel victorious.' Go to https://t.co/2IVED4IDSG to read her story #WithYouUntilPHIsnt pic.twitter.com/Js9G2wcBR7
— Actelion (@actelion_com) July 21, 2020
We understand that maintaining good mental health can be particularly difficult at this time, so here are some simple tips you can include in your daily routine to help #coronavirus #stayhome #COVID19 pic.twitter.com/Do1bI09WR6
— Actelion (@actelion_com) May 19, 2020
It’s #WorldPHDay, bringing together the global PH community to raise awareness and call for equal access to best practice care. Here at Actelion, we’ve been pledging support to advance the standards set out in the #PAHPatientCharter https://t.co/gCu8ICgp7D #WithYouUntilPHIsnt pic.twitter.com/hy5S0QJ2iZ
— Actelion (@actelion_com) May 5, 2020
Pulmonary hypertension (#PH) can impact various parts of your life, but it’s important to know that you are not alone. Visit https://t.co/RUV4npEzO0 to learn more about the experiences of other people who are learning to adapt to a life with PH #WithYouUntilPHIsnt pic.twitter.com/SN93eQUOY5
— Actelion (@actelion_com) February 18, 2020
Ferring President, Per Falk, shares his thoughts on the key topics discussed at @ESHRE 2020 and on Ferring’s commitment to building healthy families worldwide in his latest blog: https://t.co/L8ss0UHri4#eshre2020 #fertility #reproductivemedicine #maternalhealth #IVF pic.twitter.com/jJp2AiL8f2
— Ferring Pharmaceuticals (@ferring) July 8, 2020
Great to see Lee Jones, CEO of Ferring company @Rebiotix, recognised for her entrepreneurial success and pioneering work in the microbiome. #microbiome #womenleaders https://t.co/f6y6MhWlE6
— Ferring Pharmaceuticals (@ferring) May 26, 2020
Latest news ➡️ Ferring announces new data, published in @FertStert, regarding predicted high-responder patients undergoing assisted reproductive technology or #IVF. Read the press release here: https://t.co/o7NFxItPrK #pharmanews #news pic.twitter.com/8kmhuPavbJ
— Ferring Pharmaceuticals (@ferring) May 15, 2020
Ferring welcomes the Swissmedic approval of a new therapy for the prevention of excessive bleeding after birth. This first approval marks a milestone in efforts to #EndMaternalMortality.
Find out more here: https://t.co/13WpIdRxF8 #projectfamily pic.twitter.com/H9O2UpKmO1
— Ferring Pharmaceuticals (@ferring) May 13, 2020
A healthy #gutmicrobiome is important for human health. If disrupted (dysbiosis), infections like #cdiff can occur, a major world health burden. Ferring & @Rebiotix are working to help people live better lives by harnessing the #microbiome to treat recurrent C. diff. #guthealth pic.twitter.com/0s8d0bsLjG
— Ferring Pharmaceuticals (@ferring) May 7, 2020
#BreakingNews @Rebiotix a Ferring company, has announced preliminary Phase 3 findings for its investigational microbiome-based therapy for reduction of recurrent #Cdiff infection. Read more here: https://t.co/zJJ9OcgCjX #guthealth #microbiome #pharmanews #guthealth pic.twitter.com/OYAaSkdikZ
— Ferring Pharmaceuticals (@ferring) May 6, 2020
Ferring is funding #research #grants to collect data & expand knowledge on effects of #COVID19 on reproduction, #pregnancy & #neonatal health. Please share with your networks. More info: https://t.co/ReTXvZQwB4 #coronaresearch #covidresearch #projectfamily @ReprodMed @ESHRE pic.twitter.com/BIST3ffift
— Ferring Pharmaceuticals (@ferring) April 15, 2020
At Ferring, the health and safety of our patients, our employees and their families are our number one priority. For the Ferring statement on #COVID19, please visit: https://t.co/QDcVwnSf65 #fertility #IVF
— Ferring Pharmaceuticals (@ferring) March 19, 2020
Happy Labor Day! As you safely celebrate, keep in mind – hand sanitizer does not kill #cdiff spores! The #CDC recommends to #WashYourHands to protect you & your family from harmful germs that can cause deadly infections like #cdiff. https://t.co/n2ByK8d1Ny #FerringMicrobiome pic.twitter.com/KgzZUSJiLg
— Ferring USA 🇺🇸 (@FerringUSA) September 7, 2020
#DYK: Nearly 4M babies were born in the U.S. last year, a decrease of 1%. Some point to more women in the workforce & couples holding off on growing families until they have a more financially stable future as major causes: https://t.co/3vFsnWD6su#fertility #births #research
— Ferring USA 🇺🇸 (@FerringUSA) August 27, 2020
DID YOU NOW: #cdiff infection is a major public health threat according to the #CDC and can be life-threatening. A recent research letter (N=9) found that patients with #coronavirus and #cdiff had a 44% mortality rate. #MicrobiomeMonday #FerringMicrobiome pic.twitter.com/TBUsN0Bkla
— Ferring USA 🇺🇸 (@FerringUSA) August 10, 2020
Having trouble managing your #Crohns disease symptoms? Learn about a recently available treatment in the U.S.: https://t.co/IhgBN4yQes pic.twitter.com/H9VHq3xjHo
— Ferring USA 🇺🇸 (@FerringUSA) July 30, 2020
#BreakingNews Today, we are proud to announce the launch of a convenient once-daily treatment now available for mild to moderate #Crohns disease patients in the U.S. Learn more: https://t.co/IhgBN4yQes pic.twitter.com/LDrTX1zMTT
— Ferring USA 🇺🇸 (@FerringUSA) July 29, 2020
#DYK: Dysbiosis of the gut #microbiome provides a niche for deadly infections like #cdiff to flourish, often leading to a vicious cycle of recurrence. #MicrobiomeMonday #FerringMicrobiome #PowerofMicrobiome pic.twitter.com/pwM2VDjYLl
— Ferring USA 🇺🇸 (@FerringUSA) July 27, 2020
#ICYMI Ferring recently announced positive preliminary pivotal phase 3 data for RBX2660. Check out this groundbreaking investigational #microbiome based therapy for treatment of recurrent #cdiff in the news! https://t.co/bmAQWDpnjw #MicrobiomeMonday pic.twitter.com/go6VHjBRDm
— Ferring USA 🇺🇸 (@FerringUSA) June 1, 2020
Even with increased #COVID environment cleaning, did you know that 1 in 31 hospitals still have patients suffering from at least one HAIS – like #cdiff? Click here to read more: https://t.co/Q2WSakuPgH pic.twitter.com/p7fBxwqUyW
— Rebiotix Inc. (@Rebiotix) September 4, 2020
Last week, we joined the @cdiffFoundation to discuss #cdiff, the #microbiome, and the effects of #COVID-19 on a #biotech company. Click here to listen: https://t.co/tdrcti96tG pic.twitter.com/pihMaaCFej
— Rebiotix Inc. (@Rebiotix) September 2, 2020
According to the #cdc, 1 in 6 people who get #cdiff once will get it again. Check out their helpful tips in lowering recurrence risk here: https://t.co/KqlX2s54Cy pic.twitter.com/oWdXz73wfH
— Rebiotix Inc. (@Rebiotix) August 21, 2020
The #mightymicrobiome is believed to be a balancing act between viruses and bacteria. Click here to read more: https://t.co/1RidONche8 @MicrobiomeTimes pic.twitter.com/NWknZWdGx7
— Rebiotix Inc. (@Rebiotix) July 31, 2020
The #mightymicrobiome is ever changing as we age. From birth to the end of life, the #microbiome ages with us. Read more here: https://t.co/ZVqzrqwocu pic.twitter.com/wGONOc8KTC
— Rebiotix Inc. (@Rebiotix) July 29, 2020
With #WorldMicrobiomeDay next week, did you know that science shows that the human gut can help regulate mood? @my_ueg shares interesting info in their infographic. pic.twitter.com/DfiqCWcfU0
— Rebiotix Inc. (@Rebiotix) June 19, 2020
Our Head of Clinical Development – Lindy Bancke – presented at the @peggyfund 2020 National #Cdiff Advocacy Summit. Click to find out how she and the clinical team are navigating #COVID19 to keep #patientsfirst and #cdiff safety front and center. https://t.co/SsdMN3TrDD pic.twitter.com/lZklZbi9OJ
— Rebiotix Inc. (@Rebiotix) June 17, 2020
Are healthcare-associated infections, like #cdiff, becoming a growing problem as a consequence of antibiotic over-use? Click to read more: https://t.co/MAroHX18Kr pic.twitter.com/HybKVCFohh
— Rebiotix Inc. (@Rebiotix) June 4, 2020
Research compares the human #gut #microbiome to a "thriving ecosystem". @MTIG_news shares how microbiome-based therapeutics may have potential to treat a wide range of diseases Learn more: https://t.co/u0pX8tHOXW pic.twitter.com/NpGN7t8J4j
— Rebiotix Inc. (@Rebiotix) June 3, 2020
Can the human #gut #microbiota be the key to future disease prevention? Read more here: https://t.co/xYZSWGblgq pic.twitter.com/cloe8Qd0Bj
— Rebiotix Inc. (@Rebiotix) May 29, 2020
#cdiff in Covid-19 patients? See what the research of @TeenaTchopra of @waynemedicine shows here: https://t.co/9UYh8cGT99 pic.twitter.com/9Pacj4w4gd
— Rebiotix Inc. (@Rebiotix) May 28, 2020
Can foods like currants and cereal be more beneficial to the gut #microbiome? See what @EurekAlert has to say: https://t.co/PmV9pWJtIt pic.twitter.com/2xKD6tg38I
— Rebiotix Inc. (@Rebiotix) May 27, 2020
As a leader in her field, registered dietitian @AndreaHardyRD shares advice on how to get back to the basics to care of your gut #microbiome. https://t.co/0nj8oif2NH pic.twitter.com/5nzgPQZM13
— Rebiotix Inc. (@Rebiotix) May 20, 2020
With trillions of bacteria residing in one organ, the community of the human gut #microbiome is actually highly organized. Find out what @physorg_com has to say: https://t.co/KpPBCVUxP4 pic.twitter.com/0olhuXJG5m
— Rebiotix Inc. (@Rebiotix) May 19, 2020
#Cdiff infection has a high likelihood of recurrence with antibiotics; could the #microbiome help? Click to see what @MTIG_News has to share https://t.co/p9OKT7PbUk
— Rebiotix Inc. (@Rebiotix) May 15, 2020
A great piece from @GMFHx on the promise – and considerations – in connecting the #microbiome to human health: https://t.co/xYZSWGblgq pic.twitter.com/DsYLbt1yTz
— Rebiotix Inc. (@Rebiotix) May 13, 2020
Thrilled to announce Lee Jones' selection as University of Minnesota 2020 Entrepreneur of the Year https://t.co/XSjG5AzsZV @rebiotix @carlsonnews @sofiafund
— John Stavig (@gooddrjds) May 22, 2020
Last week, @Ferring-owned #microbiome firm @Rebiotix reported positive preliminary findings from its phase 3 trial for RBX2660 – a #microbiome-based therapy developed to reduce C. diff infection recurrences.@NutraNathanhttps://t.co/FOAzZxROdO
— MicrobiomePost (@MicrobiomePost) May 15, 2020